MX359516B - Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. - Google Patents

Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.

Info

Publication number
MX359516B
MX359516B MX2013011771A MX2013011771A MX359516B MX 359516 B MX359516 B MX 359516B MX 2013011771 A MX2013011771 A MX 2013011771A MX 2013011771 A MX2013011771 A MX 2013011771A MX 359516 B MX359516 B MX 359516B
Authority
MX
Mexico
Prior art keywords
preventing
methods
extracellular matrix
fibroblast proliferation
compositions
Prior art date
Application number
MX2013011771A
Other languages
English (en)
Other versions
MX2013011771A (es
Inventor
Lander Cynthia
Brophy Colleen
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of MX2013011771A publication Critical patent/MX2013011771A/es
Publication of MX359516B publication Critical patent/MX359516B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones y métodos para prevenir o tratara una enfermedad, afección o proceso patológico caracterizado por la aberrante proliferación de fibroblasto y la deposición de matriz extracelular en un tejido de un sujeto. El método incluye administrar una cantidad terapéutica de una composición farmacéutica que comprende un polipéptido que tiene la secuencia de aminoácido YAPAAARQARAKALARQLGVAA (SEQ ID NO: 1) o uno de sus equivalentes funcionales, y un portador farmacéuticamente aceptable.
MX2013011771A 2011-04-12 2012-04-12 Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. MX359516B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474370P 2011-04-12 2011-04-12
PCT/US2012/033368 WO2012142320A2 (en) 2011-04-12 2012-04-12 Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Publications (2)

Publication Number Publication Date
MX2013011771A MX2013011771A (es) 2014-07-30
MX359516B true MX359516B (es) 2018-10-01

Family

ID=47006527

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011771A MX359516B (es) 2011-04-12 2012-04-12 Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.

Country Status (15)

Country Link
US (2) US9642888B2 (es)
EP (1) EP2696888B1 (es)
JP (1) JP6031510B2 (es)
KR (1) KR101862291B1 (es)
CN (3) CN104302310A (es)
AU (1) AU2012242768B2 (es)
BR (1) BR112013026313A8 (es)
CA (2) CA2832910C (es)
DK (1) DK2696888T3 (es)
ES (1) ES2711670T3 (es)
HK (1) HK1255005A1 (es)
MX (1) MX359516B (es)
RU (1) RU2620066C2 (es)
SG (2) SG194135A1 (es)
WO (1) WO2012142320A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1976828T3 (pl) 2005-12-29 2017-07-31 Celtaxsys, Inc. Pochodne diaminy jako inhibitory hydrolazy leukotrienu a4
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
EP2575855A4 (en) * 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2696888B1 (en) 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis
FR2976587B1 (fr) * 2011-06-20 2015-04-03 Basf Beauty Care Solutions F Methode de dosage in vitro par technique immunologique
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CA2884802A1 (en) * 2012-10-31 2014-05-08 Galecto Biotech Ab Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP6527851B2 (ja) 2013-03-12 2019-06-05 セルタクシス，インコーポレイテッド ロイコトリエンａ４加水分解酵素を阻害する方法
EP2968264A4 (en) 2013-03-14 2016-11-02 Celtaxsys Inc INHIBITORS OF LEUCOTRIENE A4 HYDROLASE
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
WO2015138784A2 (en) * 2014-03-14 2015-09-17 Moerae Matrix, Inc. Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf)
US10336788B2 (en) * 2014-04-17 2019-07-02 Moerae Matrix, Inc. Inhibition of cardiac fibrosis in myocardial infarction
KR20170083063A (ko) * 2014-11-17 2017-07-17 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법
BR112017014737A2 (pt) 2015-01-08 2018-01-16 Moerae Matrix Inc formulação de peptídeos inibidores de mk2
CN107921082A (zh) * 2015-03-12 2018-04-17 莫伊莱麦屈克斯公司 含有mk2抑制剂肽的组合物用于治疗非小细胞肺癌的用途
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN107987128B (zh) * 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
JP7471660B2 (ja) 2018-05-17 2024-04-22 アクチュエイト セラピューティクス インク． グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
CN109406795A (zh) * 2018-11-20 2019-03-01 昆明医科大学 一种轻型脑外伤的血清分子诊断标记物及应用
WO2021040673A1 (en) * 2019-08-26 2021-03-04 Alain Martin Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd
USD958124S1 (en) 2019-12-16 2022-07-19 Samsung Electronics Co., Ltd. Television receiver
USD978094S1 (en) 2019-12-27 2023-02-14 Samsung Electronics Co., Ltd. Television receiver
WO2021146662A1 (en) * 2020-01-17 2021-07-22 Muhammed Majeed Therapeutic compositions and methods for pulmonary fibrosis
CN112386682B (zh) * 2020-02-12 2022-12-06 王斌 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用
US20230127499A1 (en) * 2020-03-30 2023-04-27 Figene, Llc Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus
EP4142751A4 (en) * 2020-04-01 2025-01-08 Figene, LLC Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards)
US11505584B2 (en) * 2020-04-21 2022-11-22 Remodeless Cv Ltd Therapy for reducing brain damage
USD989726S1 (en) 2020-12-03 2023-06-20 Samsung Electronics Co., Ltd. Television receiver
AU2021390125A1 (en) * 2020-12-03 2023-06-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition comprising anti-connective tissue growth factor antibody
USD989017S1 (en) 2020-12-03 2023-06-13 Samsung Electronics Co., Ltd. Television receiver
US20220202852A1 (en) * 2020-12-30 2022-06-30 Briotech, Inc. Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions
WO2022204045A1 (en) * 2021-03-22 2022-09-29 Spiritus Therapeutics, Inc. Diagnostic and therapeutic uses of purified potent exosomes containing disease-based and therapy based signature cargo
CN113440431A (zh) * 2021-08-02 2021-09-28 山西锦波生物医药股份有限公司 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品
CN116262112A (zh) * 2021-12-14 2023-06-16 南京安吉生物科技有限公司 一种雾化吸入用融合多肽制剂及其制备方法和应用
KR20240134978A (ko) 2022-01-14 2024-09-10 상하이 한서 바이오메디컬 컴퍼니 리미티드 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도
CN114522221B (zh) * 2022-02-28 2024-04-19 中国人民解放军陆军特色医学中心 分泌蛋白ctgf在用于制备治疗急性肺损伤药物中的应用
WO2023178169A2 (en) * 2022-03-15 2023-09-21 Anemoi Biotech Holdings, Inc. Compositions and methods for treating the pathophysiology of severe viral infection
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用
CN117577330B (zh) * 2024-01-15 2024-04-02 北京大学 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
PT83094B (pt) 1985-07-30 1993-07-30 Glaxo Group Ltd Dispositivos proprios para a administracao de medicamentos a pacientes
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DE69333955D1 (de) 1992-04-24 2006-02-02 Stanford Res Inst Int Targeting homologer sequenzen in eukaryotenzellen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
PT733059E (pt) 1993-12-09 2001-03-30 Univ Jefferson Compostos e metodos para mutacoes dirigidas ao local em celulas eucarioticas
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
KR20110017465A (ko) * 2002-04-25 2011-02-21 더 스크립스 리서치 인스티튜트 폐질환 증상의 치료 및 예방
AR040603A1 (es) * 2002-07-19 2005-04-13 Abbott Lab S A El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos
DK1753302T3 (da) * 2003-11-25 2011-08-15 Virginia Tech Intell Prop Sammensætning til dyrefoder og fremgangsmåde til at reducere map-kinaseaktivitet
WO2005110410A2 (en) * 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
JP2008510825A (ja) 2004-08-23 2008-04-10 マンカインド コーポレイション ホスホジエステラーゼ５型の阻害剤の肺送達
CN101227918A (zh) * 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
KR101486397B1 (ko) 2005-09-14 2015-01-28 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
KR20080096809A (ko) 2006-02-22 2008-11-03 맨카인드 코포레이션 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
JP2009532489A (ja) * 2006-04-03 2009-09-10 テバ ファーマシューティカル インダストリーズ リミティド 薬剤微粒子
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
WO2008098096A1 (en) * 2007-02-08 2008-08-14 Boehringer Ingelheim International Gmbh Anti-cytokine heterocyclic compounds
US20080282320A1 (en) 2007-05-11 2008-11-13 Denovo Andrew Security Compliance Methodology and Tool
US20110017340A1 (en) 2007-12-21 2011-01-27 Cabot Corporation Syntactic Foam Compositions, Pipelines Insulated with Same, and Method
DK2349310T3 (da) 2008-10-20 2014-08-11 Moerae Matrix Inc Polypeptid til behandling eller forebyggelse af adhæsioner
EP2378875B1 (en) 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
EP2575855A4 (en) * 2010-05-24 2014-03-12 Moerae Matrix Inc METHOD FOR TREATING OR PREVENTING VASCULAR GRAFT BREAKAGE
EP2696888B1 (en) 2011-04-12 2018-12-05 Moerae Matrix, Inc., Compositions and methods for preventing or treating pulmonary fibrosis

Also Published As

Publication number Publication date
CN111110850A (zh) 2020-05-08
DK2696888T3 (en) 2019-03-25
US9642888B2 (en) 2017-05-09
CN108014340A (zh) 2018-05-11
BR112013026313A2 (pt) 2016-12-27
CA3042808A1 (en) 2012-10-18
KR101862291B1 (ko) 2018-05-29
WO2012142320A2 (en) 2012-10-18
CN104302310A (zh) 2015-01-21
WO2012142320A3 (en) 2015-06-11
SG194135A1 (en) 2013-11-29
CA2832910A1 (en) 2012-10-18
AU2012242768A1 (en) 2013-10-24
ES2711670T3 (es) 2019-05-06
CA2832910C (en) 2019-07-02
RU2013150249A (ru) 2015-05-20
EP2696888A4 (en) 2016-04-20
KR20140063517A (ko) 2014-05-27
US20190022169A1 (en) 2019-01-24
WO2012142320A8 (en) 2014-02-20
AU2012242768B2 (en) 2017-10-12
JP2014533235A (ja) 2014-12-11
EP2696888A2 (en) 2014-02-19
SG10201604560TA (en) 2016-07-28
JP6031510B2 (ja) 2016-11-24
MX2013011771A (es) 2014-07-30
NZ616672A (en) 2016-04-29
BR112013026313A8 (pt) 2018-01-30
EP2696888B1 (en) 2018-12-05
HK1255005A1 (zh) 2019-08-02
US20120263680A1 (en) 2012-10-18
RU2620066C2 (ru) 2017-05-22

Similar Documents

Publication Publication Date Title
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2017006372A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular.
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
IL308807B1 (en) Combination therapy for cancer treatment
NZ621868A (en) Growth hormone polypeptides and methods of making and using same
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
HK1204988A1 (en) Methods and compositions for preventing or treating ophthalmic conditions
WO2012012600A3 (en) Peptide compounds for regulating the complement system
PH12014500715A1 (en) Treatment of rhinitis
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
JP2018506506A (ja) 神経変性障害
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX382978B (es) Método para tratar enfermedades de los ojos asociadas con inflamación o proliferación vascular.
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CA2634902A1 (en) Anticancer agent comprising a peptide
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MOERAE MATRIX, INC.

FG Grant or registration